IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer

What Was Tested

Researchers studied IGF-1 LR3 in this randomized controlled trial publication.

Since the growth hormone-insulin-like growth factor (GH-IGF-1) axis has been implicated in prostate tumorigenesis, the researchers aimed to evaluate the association between IGF-1 and its binding proteins on outcomes in men with metastatic PCa treated with ADT, with or without docetaxel (D).

Why It Was Studied

Androgen deprivation therapy (ADT) forms the cornerstone of treatment in locally advanced and metastatic prostate cancer (PCa).

The researchers analyzed serum samples for IGF-1 and its family proteins from baseline, 6 months post-randomization, and at the time of progression in men enrolled to receive ADT +/- D in the phase 3 CHAARTED trial.

Who Took Part

The abstract describes 560 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

A time span of 6 months appears in the methods.

What Was Measured

The key outcomes were time to the development of castrate-resistant prostate cancer and overall survival (OS).

PubMed files the paper under topics including Insulin-Like Growth Factor I, Docetaxel, Androgen Antagonists, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Neoplasm Metastasis.

Author keywords: IGF-1, IGF-BP1, androgen deprivation therapy and metabolism.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in 560 patients over 6 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2023 (Endocrine-related cancer), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.